Pantginis emphasizes that VK2735, a dual GLP-1/GIP receptor agonist, may demonstrate superior weight loss outcomes compared to semaglutide ... s CagriSema trials present an opportunity for Viking ...
Viking Therapeutics (VKTX) announced the initiation of a Phase 2 clinical trial of the oral tablet formulation of VK2735, the company’s dual agonist of the glucagon-like peptide 1 and glucose ...
Novo Nordisk reported that adults with obesity achieved significant weight loss using their semaglutide ... CagriSema. The maintained Buy rating and price target reflect a positive outlook for ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback